Figure 3.

Effects of the PPARδ agonist, selective inhibitor of MEK/ERK1/2, and EGF receptor-selective tyrosine kinase inhibitor on protein expression of Δ6-desaturase (Δ6D) in PANC-1 human pancreatic tumor cells. Cells were treated with GW0742, PD98059, or AG1478 as indicated. Cell lysates were analyzed for Δ6 desaturase and β-actin. Molecular weight markers are shown. Δ6 desaturase levels were detected by Western blots, quantified, normalized to β-actin, and represented as mean ± SE from 3 independent experiments. * and **: P < 0.05 and P < 0.01 for Student's t-test, respectively.